{"DataElement":{"publicId":"14513862","version":"1","preferredName":"Plasma Cell Myeloma ISS Stage","preferredDefinition":"The plasma cell myeloma ISS stage.","longName":"2688930v1.00:14513861v1.00","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"2688930","version":"1","preferredName":"Plasma Cell Myeloma Stage","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)_The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"PLSM_CL_MY_STG","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2647790","version":"1","preferredName":"Myeloma","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) -- 2003","longName":"C3242","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32446690-9562-2995-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2224086","version":"1","preferredName":"Stage","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63F1A4F-0A96-5494-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-03","endDate":null,"createdBy":"UMLLOADER_CAMOD","dateCreated":"2005-05-03","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C63AF-66BE-65EE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"14513861","version":"1","preferredName":"ISS for Myeloma Neoplasm Stage","preferredDefinition":"A method of staging myeloma published by the International Myeloma Working Group in 2003._The extent of a cancer in the body.","longName":"14513861v1.00","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage 1","valueDescription":null,"ValueMeaning":{"publicId":"3928731","version":"1","preferredName":"ISS Stage I Plasma Cell Myeloma","longName":"3928731","preferredDefinition":"Plasma cell myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ISS Stage I Multiple Myeloma","conceptCode":"C70658","definition":"Multiple myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97D61EC-FF5F-F81E-E040-BB89AD435714","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0684BD95-91F4-0B65-E063-731AD00A1CB9","beginDate":"2023-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-29","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","deletedIndicator":"No"},{"value":"Stage 2","valueDescription":null,"ValueMeaning":{"publicId":"2689277","version":"1","preferredName":"ISS Stage II Plasma Cell Myeloma","longName":"2689277","preferredDefinition":"Plasma cell myeloma with beta-2-microglobulin less than 3.5 and albumin less than 3.5 or beta-2-microglobulin 3.5 to less than 5.5 (median survival of 44 months).  Note that the older Durie/Salmon staging system defines stage II quite differently. (PDQ)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ISS Stage II Multiple Myeloma","conceptCode":"C70659","definition":"Multiple myeloma with blood levels of beta-2-microglobulin between 3.5 and 5.5 mg/L.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4DC21A-8C70-4383-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0684BD95-91F5-0B65-E063-731AD00A1CB9","beginDate":"2023-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-29","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","deletedIndicator":"No"},{"value":"Stage 3","valueDescription":null,"ValueMeaning":{"publicId":"2689276","version":"1","preferredName":"ISS Stage III Plasma Cell Myeloma","longName":"2689276","preferredDefinition":"Plasma cell myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ISS Stage III Multiple Myeloma","conceptCode":"C70660","definition":"Multiple myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4DC21A-8C49-4383-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0684BD95-91F6-0B65-E063-731AD00A1CB9","beginDate":"2023-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-29","modifiedBy":"KUMMEROA","dateModified":"2023-09-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2689274","version":"1","preferredName":"International Staging System for Myeloma Stage","preferredDefinition":"A method of staging myeloma published by the International Myeloma Working Group in 2003.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C70657:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Staging System for Myeloma","conceptCode":"C70657","definition":"A method of staging myeloma published by the International Myeloma Working Group in 2003.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4DC186-5382-2DC6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ONEDATA","dateModified":"2007-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0684B210-4CF8-099E-E063-731AD00AA756","latestVersionIndicator":"Yes","beginDate":"2023-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-29","modifiedBy":"ZHWENDY","dateModified":"2023-10-23","changeDescription":null,"administrativeNotes":"2023.9.29 Created per ticket request CADSR0002904. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the plasma cell myeloma ISS stage?","url":null,"context":"Alliance"},{"name":"Alliance Text 1","type":"Alternate Question Text","description":"ISS stage at time of enrollment:","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0684D226-6EBE-11AA-E063-731AD00A9420","latestVersionIndicator":"Yes","beginDate":"2023-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-29","modifiedBy":"ZHWENDY","dateModified":"2023-10-23","changeDescription":null,"administrativeNotes":"2023.9.29 Created per ticket request CADSR0002904. ak","unresolvedIssues":null,"deletedIndicator":"No"}}